Elise C. Kohn, M.D.
Medical Oncology Branch and Affiliates
Head, Molecular Signaling Section
Head, Women's Cancers Clinic
Senior Investigator
National Cancer Institute
9000 Rockville Pike
Building 10, Room 12N226, MSC 1906
Bethesda, MD 20892
Phone: 301-402-2726
Fax: 301-480-5142
kohne@mail.nih.gov
Dr. Kohn is a graduate of the University of Michigan Medical School where she also completed residency training in internal medicine; she came to NCI for medical oncology training in the Medicine Branch. Dr. Kohn then joined the Laboratory of Pathology to investigate ovarian cancer and signal transduction molecular targets in invasion and angiogenesis, and she maintained her clinical focus in the translational clinical studies of ovarian cancer. Recently, Dr. Kohn has been involved in the identification and characterization of two proteins involved in ovarian cancer and cellular stress. In parallel, her clinical work has evolved to include the newest proteomic technologies applied to early detection testing and validation of therapeutic targets in clinical trials. Dr. Kohn also applies the advanced proteomic applications to her laboratory studies of stress pathways, growth factor regulation, and angiogenesis.
Dr. Kohn serves on numerous NIH and NCI committees, and she is the newly elected chair of the Integration Panel of the Department of Defense Ovarian Cancer Research Program. Dr. Kohn is a participating member and protocol investigator in the Gynecologic Oncology Group, judges the Fellows Award for Research Excellence competition yearly, and is the co-chair of the Breast and Gynecologic Malignancies Faculty. She was recognized with the NCI Diversity Award and Mentor of Merit Award in 2007. Dr. Kohn was elected a fellow of the American Association for the Advancement of Science.
Dr. Kohn's Clinical Trial(s):
NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with breast cancer, fallopian tube cancer, ovarian cancer, primary peritoneal cancer, or solid tumors. Click on the trial(s) below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the study team directly.
The quality of these videocasts is dependent on the speed of your Internet connection. Many videocasts are streamed directly to your computer by software on the NIH VideoCasting Web site. Others require that you have a standalone player installed on your computer to handle the streaming. If you do not have a standalone player installed or if you are having problems viewing the videocast, please visit http://videocast.nih.gov/faq/.
|
CC Grand Rounds: (1) PARP Inhibitors: How Successful Have We Been in Modulating DNA Damage? (2) The Evolving Role of PARP Inhibitors in Breast and Ovarian Cancers Speaker(s): Shivaani Kummar, MD, Head, Early Clinical Trials Development, Office of the Director, Division of Cancer Treatment and Diagnosis, NCI March 23, 2011 63 minutes http://videocast.nih.gov/launch.asp?16541 |
Some of the resources above require the use of a standalone player: Download Free RealPlayer 
Back to Top
Clinical Trials Research
CONVERGENCE OF SURVIVAL, PROLIFERATION, AND INVASION SIGNALS AS TRANSLATIONAL MOLECULAR TARGETS: Discovery and candidate identification approaches applied to ovarian cancer
Our working hypothesis posits there is a convergence of prosurvival, angiogenesis, and motility signals at common pathways in the local tumor microenvironment and these events can be efficiently targeted therapeutically. This Section previously focused on the role of Ca++ as a regulator of gene expression and cellular physiology in pathways of angiogenesis and ovarian cancer (ovca).
Read more
 | Watch/Listen to Dr. Kohn's videocast/podcast |
